A Fluorescent Imaging Probe Based on a Macrocyclic Scaffold That Binds to Cellular EpCAM

Journal of Molecular Evolution

Volumn 81, Issue 5-6, 2015, Pages 210-217

  Iwasaki, Kazuhiro ^a   Goto, Yuki ^a   Katoh, Takayuki ^a   Yamashita, Taro ^b   Kaneko, Shuichi ^b   Suga, Hiroaki ^a,c  

^a UNIVERSITY OF TOKYO   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

Cancer cell imaging; EpCAM; Fluorescent imaging probe; In vitro selection; Macrocyclic peptide

Indexed keywords

CELL ADHESION MOLECULE; CYCLOPEPTIDE; EPCAM PROTEIN, HUMAN; FLUORESCENT DYE; MOLECULAR PROBE; PEPTIDE APTAMER; PROTEIN BINDING; TUMOR ANTIGEN;

FLUORESCENCE IMAGING; HUMAN; MCF 7 CELL LINE; METABOLISM; MOLECULAR PROBE; NEOPLASMS; SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT APTAMER TECHNIQUE;

ANTIGENS, NEOPLASM; APTAMERS, PEPTIDE; CELL ADHESION MOLECULES; FLUORESCENT DYES; HUMANS; MCF-7 CELLS; MOLECULAR PROBES; NEOPLASMS; OPTICAL IMAGING; PEPTIDES, CYCLIC; PROTEIN BINDING; SELEX APTAMER TECHNIQUE;

EID: 84948387195     PISSN: 00222844     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00239-015-9710-z     Document Type: Article

References (44)

1. Armstrong A, Eck SL (2003) EpCAM: a new therapeutic target for an old cancer antigen. Cancer Biol Ther 2:320–326
2. Baeuerle PA, Gires O (2007) EpCAM (CD326) finding its role in cancer. Br J Cancer 96:417–423. doi:10.1038/sj.bjc.6603494
3. Chaudry MA, Sales K, Ruf P, Lindhofer H, Winslet MC (2007) EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges. Br J Cancer 96:1013–1019. doi:10.1038/sj.bjc.6603505
4. Cirulli V et al (1998) KSA antigen Ep-CAM mediates cell-cell adhesion of pancreatic epithelial cells: morphoregulatory roles in pancreatic islet development. J Cell Biol 140:1519–1534
5. Deonarain MP, Kousparou CA, Epenetos AA (2009) Antibodies targeting cancer stem cells: a new paradigm in immunotherapy? MAbs 1:12–25
6. Goto Y, Ohta A, Sako Y, Yamagishi Y, Murakami H, Suga H (2008) Reprogramming the translation initiation for the synthesis of physiologically stable cyclic peptides. ACS Chem Biol 3:120–129. doi:10.1021/cb700233t
7. Goto Y, Katoh T, Suga H (2011) Flexizymes for genetic code reprogramming. Nat Protoc 6:779–790. doi:10.1038/nprot.2011.331
8. Guillemot JC, Naspetti M, Malergue F, Montcourrier P, Galland F, Naquet P (2001) Ep-CAM transfection in thymic epithelial cell lines triggers the formation of dynamic actin-rich protrusions involved in the organization of epithelial cell layers. Histochem Cell Biol 116:371–378. doi:10.1007/s004180100329
9. Hayashi Y, Morimoto J, Suga H (2012) In vitro selection of anti-Akt2 thioether-macrocyclic peptides leading to isoform-selective inhibitors. ACS Chem Biol 7:607–613. doi:10.1021/cb200388k
10. Hristodorov D et al (2014) EpCAM-selective elimination of carcinoma cells by a novel MAP-based cytolytic fusion protein. Mol Cancer Ther 13:2194–2202. doi:10.1158/1535-7163.MCT-13-0781
11. Huls GA et al (1999) A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments. Nat Biotechnol 17:276–281. doi:10.1038/7023
12. Hussain S, Pluckthun A, Allen TM, Zangemeister-Wittke U (2006) Chemosensitization of carcinoma cells using epithelial cell adhesion molecule-targeted liposomal antisense against bcl-2/bcl-xL. Mol Cancer Ther 5:3170–3180. doi:10.1158/1535-7163.MCT-06-0412
13. Ito K et al (2015) Artificial human Met agonists based on macrocycle scaffolds. Nat Commun 6:6373. doi:10.1038/ncomms7373
14. Iwasaki K, Goto Y, Katoh T, Suga H (2012) Selective thioether macrocyclization of peptides having the N-terminal 2-chloroacetyl group and competing two or three cysteine residues in translation. Org Biomol Chem 10:5783–5786. doi:10.1039/c2ob25306b
15. Jung YK, Woo MA, Soh HT, Park HG (2014) Aptamer-based cell imaging reagents capable of fluorescence switching. Chem Commun (Camb) 50:12329–12332. doi:10.1039/c4cc03888f
16. Kodan A et al (2014) Structural basis for gating mechanisms of a eukaryotic P-glycoprotein homolog. Proc Natl Acad Sci USA 111:4049–4054. doi:10.1073/pnas.1321562111
17. Kratz H, Haeckel A, Michel R, Schonzart L, Hanisch U, Hamm B, Schellenberger E (2012) Straightforward thiol-mediated protein labelling with DTPA: Synthesis of a highly active 111In-annexin A5-DTPA tracer. EJNMMI Res 2:17. doi:10.1186/2191-219X-2-17
18. Kwiatkowska-Borowczyk EP, Gabka-Buszek A, Jankowski J, Mackiewicz A (2015) Immunotargeting of cancer stem cells. Contemp Oncol (Pozn) 19:A52–A59. doi:10.5114/wo.2014.47129
19. Ladwein M et al (2005) The cell-cell adhesion molecule EpCAM interacts directly with the tight junction protein claudin-7. Exp Cell Res 309:345–357. doi:10.1016/j.yexcr.2005.06.013
20. Linke R, Klein A, Seimetz D (2010) Catumaxomab: clinical development and future directions. MAbs 2:129–136
21. Litvinov SV et al (1997) Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. J Cell Biol 139:1337–1348
22. Maetzel D et al (2009) Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 11:162–171. doi:10.1038/ncb1824
23. Martin-Killias P, Stefan N, Rothschild S, Pluckthun A, Zangemeister-Wittke U (2011) A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity. Clin Cancer Res 17:100–110. doi:10.1158/1078-0432.CCR-10-1303
24. Morimoto J, Hayashi Y, Suga H (2012) Discovery of macrocyclic peptides armed with a mechanism-based warhead: isoform-selective inhibition of human deacetylase SIRT2. Angew Chem Int Ed Engl 51:3423–3427. doi:10.1002/anie.201108118
25. Morioka T, Loik ND, Hipolito CJ, Goto Y, Suga H (2015) Selection-based discovery of macrocyclic peptides for the next generation therapeutics. Curr Opin Chem Biol 26:34–41. doi:10.1016/j.cbpa.2015.01.023
26. Munz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O (2004) The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 23:5748–5758. doi:10.1038/sj.onc.1207610
27. Nemoto N, Miyamoto-Sato E, Husimi Y, Yanagawa H (1997) In vitro virus: bonding of mRNA bearing puromycin at the 3′-terminal end to the C-terminal end of its encoded protein on the ribosome in vitro. FEBS Lett 414:405–408
28. Nochi T et al (2004) Biological role of Ep-CAM in the physical interaction between epithelial cells and lymphocytes in intestinal epithelium. Clin Immunol 113:326–339. doi:10.1016/j.clim.2004.08.013
29. Osta WA et al (2004) EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 64:5818–5824. doi:10.1158/0008-5472.CAN-04-0754
30. Passioura T, Katoh T, Goto Y, Suga H (2014) Selection-based discovery of druglike macrocyclic peptides. Annu Rev Biochem 83:727–752. doi:10.1146/annurev-biochem-060713-035456
31. Patriarca C, Macchi RM, Marschner AK, Mellstedt H (2012) Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat Rev 38:68–75. doi:10.1016/j.ctrv.2011.04.002
32. Roberts RW, Szostak JW (1997) RNA-peptide fusions for the in vitro selection of peptides and proteins. Proc Natl Acad Sci USA 94:12297–12302
33. Shaunak S et al (2006) Site-specific PEGylation of native disulfide bonds in therapeutic proteins. Nat Chem Biol 2:312–313. doi:10.1038/nchembio786
34. Song Y et al (2013) Selection of DNA aptamers against epithelial cell adhesion molecule for cancer cell imaging and circulating tumor cell capture. Anal Chem 85:4141–4149. doi:10.1021/ac400366b
35. Spizzo G et al (2004) High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat 86:207–213. doi:10.1023/B:BREA.0000036787.59816.01
36. Spizzo G et al (2006) Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol 103:483–488. doi:10.1016/j.ygyno.2006.03.035
37. Stefan N, Martin-Killias P, Wyss-Stoeckle S, Honegger A, Zangemeister-Wittke U, Pluckthun A (2011) DARPins recognizing the tumor-associated antigen EpCAM selected by phage and ribosome display and engineered for multivalency. J Mol Biol 413:826–843. doi:10.1016/j.jmb.2011.09.016
38. Subramanian N, Sreemanthula JB, Balaji B, Kanwar JR, Biswas J, Krishnakumar S (2014) A strain-promoted alkyne-azide cycloaddition (SPAAC) reaction of a novel EpCAM aptamer-fluorescent conjugate for imaging of cancer cells. Chem Commun (Camb) 50:11810–11813. doi:10.1039/c4cc02996h
39. Tanaka Y et al (2013) Structural basis for the drug extrusion mechanism by a MATE multidrug transporter. Nature 496:247–251. doi:10.1038/nature12014
40. Trzpis M, McLaughlin PM, de Leij LM, Harmsen MC (2007) Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol 171:386–395. doi:10.2353/ajpath.2007.070152
41. Went P, Dirnhofer S, Salvisberg T, Amin MB, Lim SD, Diener PA, Moch H (2005) Expression of epithelial cell adhesion molecule (EpCam) in renal epithelial tumors. Am J Surg Pathol 29:83–88
42. Went P et al (2006) Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Br J Cancer 94:128–135. doi:10.1038/sj.bjc.6602924
43. Yamagishi Y, Shoji I, Miyagawa S, Kawakami T, Katoh T, Goto Y, Suga H (2011) Natural product-like macrocyclic N-methyl-peptide inhibitors against a ubiquitin ligase uncovered from a ribosome-expressed de novo library. Chem Biol 18:1562–1570. doi:10.1016/j.chembiol.2011.09.013
44. Zielonka S et al (2014) Shark Attack: high affinity binding proteins derived from shark vNAR domains by stepwise in vitro affinity maturation. J Biotechnol 191:236–245. doi:10.1016/j.jbiotec.2014.04.023